Sigma-Aldrich Corp.’s custom manufacturing business unit, SAFC Commercial is expanding its facility in Carlsbad, CA to further enhance clinical and commercial bulk drug production capabilities, as well as fill/finish of viral products for its gene therapy, viral vaccine and immunotherapy customers.
 
“Gene therapy is an emerging technology, and our SAFC and BioReliance sites in Carlsbad, Rockville, MD and GlasgowScotland, have supported this growing industry for years,” said Gilles Cottier, president of SAFC. “This investment is pivotal to our customers and reflects SAFC’s continued dedication to providing the infrastructure customers need to bring their drugs to market.”
 
The investment was driven by continued interest in targeted gene therapies for indications such as hemophilia and cancer immunotherapies (CAR-T cells). Utilizing the biosafety testing expertise of BioReliance, the Carlsbad facility provides a full range of GMP manufacturing and testing services.